Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease

Summary

This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of Afimkibart (RO7790121, RVT-3101) in adult participants with moderate to severe active Crohn's disease.

Timeline

Start

2023-07-24

Primary completion

2026-12-31

Completion

2026-12-31

Drugs

Indications